Clinical Report: Challenges in Corneal Tissue Reimbursement and Impact on Care

Overview

Corneal tissue procedures, though low in volume compared to cataract surgeries, are critical and often sight-saving. However, reimbursement gaps, especially with Medicare Advantage and private insurers, place financial strain on ASCs and eye banks, potentially delaying patient care.

Background

Corneal transplants are essential procedures that restore vision but are performed far less frequently than cataract surgeries. Eye banks supply corneal tissue at cost without profit, and reimbursement issues arise primarily with Medicare Advantage and private insurance plans. These reimbursement challenges affect ambulatory surgery centers (ASCs) and eye banks, leading to financial losses or reduced procedure volumes. Understanding insurance contracts and securing appropriate reimbursement is vital to maintaining access to corneal transplant care.

Data Highlights

Key Findings

• Corneal tissue procedures are low volume but high impact, often restoring sight.
• Medicare Advantage and private insurers frequently under-reimburse corneal tissue fees, unlike traditional Medicare.
• Eye banks cannot mark up tissue costs and face financial losses when discounts are requested.
• Reimbursement failures may cause ASCs to reduce corneal procedures or shift them to hospitals.
• Patients may experience delays in sight-restoring surgeries due to reimbursement policies.
• ASCs benefit from consulting with eye banks or reimbursement experts before signing insurance contracts.

Clinical Implications

Clinicians and ASC administrators should prioritize reviewing insurance contracts for corneal tissue reimbursement terms, especially with Medicare Advantage and private insurers. Collaborating with eye banks or reimbursement consultants can help secure appropriate payment, ensuring continued access to sight-saving corneal transplant procedures. Awareness of reimbursement challenges can prevent delays in patient care and avoid shifting procedures to less optimal settings.

Conclusion

Addressing reimbursement gaps for corneal tissue is essential to sustain ASC viability and timely patient access to vision-restoring surgeries. Proactive contract review and collaboration with eye banks are key strategies to overcome these financial barriers.

References

1. Rossi T et al. 2023 -- The Conundrum of Corneal Tissue Reimbursement